Company intelligence / Profile preview

Mural Oncology

Dublin, Leinster, Irelandmuraloncology.com ↗

Ownership: Public · MURA
Employees: ~10
Development stage: Phase 3

Overview

Mural Oncology was a clinical-stage biotech focused on engineered cytokine immunotherapies. Its lead program nemvaleukin alfa failed both its pivotal phase 3 trial in platinum-resistant ovarian cancer and phase 2 trial in mucosal/melanoma as of April 2025. The company has since terminated all clinical development and laid off ~90% of staff while seeking strategic alternatives. Two preclinical assets—engineered forms of interleukins IL–18 and split-targeted IL–12—remain but have not entered human trials.[7][10][8]

Therapeutic areas: Oncology
Modalities: Engineered cytokinesProtein therapeutics
Industry: Biotech

Drug pipeline

4 assets

nemvaleukin alfa

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $35.4M
Total revenue: $0
Enterprise value: $-19.9M

Beyond the preview

Go deeper on Mural Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mural Oncology.

Explore the full profile